Journal of Leukemia & Lymphoma 2019;28(12):724-727

doi:10.3760/cma.j.issn.1009-9921.2019.12.006

Treatment progress of mantle cell lymphoma

Yimin REN 1 ; Wei XU

Affiliations

+expand

Keywords

Lymphoma, mantle-cell; Lymphoma, non-Hodgkin; Molecular targeted therapy; Immunotherapy; Chimeric antigen receptor T cell

Country

China

Language

Chinese

Abstract

Mantle cell lymphoma (MCL) is a subtype of aggressive B-cell non-Hodgkin lymphoma(NHL) with a heterogeneous clinical characteristics, accounting for 3%-10% of adult-onset NHL. With the great advance of novel drugs, the therapeutic options for MCL are constantly updating. The 61st American Society of Hematology Annual Meeting reported the recent treatment progress of MCL including novel drugs,combinations of nonchemotherapeutic agents and chimeric antigen receptor T-cell therapy. This paper focuses on the treatment progress of MCL.